<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460146</url>
  </required_header>
  <id_info>
    <org_study_id>CXA-10-202</org_study_id>
    <nct_id>NCT02460146</nct_id>
  </id_info>
  <brief_title>PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complexa, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complexa, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to demonstrate the safety, tolerability and&#xD;
      pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral&#xD;
      doses over 14 days to healthy obese male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complexa has developed an oral formulation of CXA-10. The main purpose of this trial is to&#xD;
      demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its&#xD;
      metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese&#xD;
      male volunteers. The pharmacodynamic (PD) effects of CXA-10 on serum biomarkers, some of&#xD;
      which are elevated in the obese population, will also be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events) and tolerability of multiple ascending oral doses of CXA 10 administered daily for 14 days</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>CXA-10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CXA-10 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo contains olive oil with BHT (0.08% to 0.10%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXA-10</intervention_name>
    <description>CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid</description>
    <arm_group_label>CXA-10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CXA-10 placebo</intervention_name>
    <description>The placebo contains olive oil with BHT (0.08% to 0.10%).</description>
    <arm_group_label>CXA-10 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &gt;27 and ≤40 kg/m2&#xD;
&#xD;
          -  In good general health as determined by a thorough medical history and physical&#xD;
             examination, ECG, vital signs, and clinical laboratory evaluation&#xD;
&#xD;
          -  Results of clinical laboratory tests must be without clinically significant&#xD;
             abnormalities for this population and may exceed the limits of the reference ranges,&#xD;
             including hematology, clinical chemistry and urinalysis except as noted below&#xD;
&#xD;
          -  Hemoglobin A1c (HbA1c) &lt;7%&#xD;
&#xD;
          -  Average blood pressure &lt;160/100 mmHg at screening&#xD;
&#xD;
          -  QTcF interval (Fredericia's correction factor) must be ≤430 msec at screening and&#xD;
             pre-dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormality for this population identified on the screening&#xD;
             history, physical or laboratory examinations, or any other medical condition or&#xD;
             circumstance making the volunteer unsuitable for participation in the study&#xD;
&#xD;
          -  Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations,&#xD;
             personal or family history of congenital prolonged QT syndromes or sudden unexpected&#xD;
             death due to a cardiac reason&#xD;
&#xD;
          -  History of any primary malignancy, including a history of melanoma or suspicious&#xD;
             undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas&#xD;
             of the skin or cervical carcinoma in situ or other malignancies curatively treated and&#xD;
             with no evidence of disease for at least 5 years&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 21 units/week (one unit = 125 mL of&#xD;
             wine or 284 mL of beer or a single 25 mL measure of spirits) within 6 months of&#xD;
             screening&#xD;
&#xD;
          -  Treatment with any prescription or non-prescription drugs (including vitamins, herbal&#xD;
             and dietary supplements) within 7 days or 5 half-lives, whichever is longer, prior to&#xD;
             dosing and until collection of the final PK sample. Use of any drug including aspirin&#xD;
             or non-steroidal anti-inflammatory drugs (NSAIDs) must be avoided within 7 days prior&#xD;
             to the first dose and during this study as it may interfere with the pharmacology of&#xD;
             CXA-10. Use of high energy supplements or drinks (especially, those containing&#xD;
             caffeine, protein supplements, and weight loss drugs)&#xD;
&#xD;
          -  History of smoking, including e-cigarettes, or use of nicotine-containing products&#xD;
             within 1 month of screening&#xD;
&#xD;
          -  Resting heart rate ≥100 BPM after 5 minutes rest (as above) at the screening visit&#xD;
&#xD;
          -  Subjects with any other clinically relevant ECG parameter abnormality (e.g., PR&#xD;
             interval, QRS deviation) or any clinically significant ECG abnormality will be&#xD;
             excluded from the study&#xD;
&#xD;
          -  Any clinically significant murmurs evident on auscultation of the heart (including&#xD;
             evidence of mitral valve prolapse)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Blok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jasper Clinic, Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jasper Clinical Research &amp; Development, Inc.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CXA-10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

